Editor’s note: This research was published in JAMA Cardiology on Sept. 21, 2022.
PCI improves angina-related quality of life in patients with STEMI and multi-vessel CAD – no matter whether that involves culprit-only lesions or complete revascularization.
PHRI Senior Scientist Shamir Mehta presented this finding of a pre-specified analysis of the COMPLETE trial at ACC 2022 today in Washington, DC, as Featured Clinical Research.
Mehta told TCTMD that “this analysis looked at patient-reported outcomes, so these are patients telling us how they feel and how the quality of their life has improved. I think it’s complementary to the hard outcomes [in COMPLETE] that were reported by physicians, with a very clear benefit in preventing angina.” He added:
“Although the [improved QoL] finding is likely intuitive to many practicing interventional cardiologists, this is the first time we’ve actually shown it.”
C. Michael Gibson interviewed Mehta on the results of the new pre-specified analysis during the ACC 2022 event.
The study that stood out the most at ACC 2022
Deepak Bhatt, a doctor and researcher at Brigham and Women’s Hospital, named COMPLETE’s analysis as a highlight of ACC for him. This Practical Cardiology article includes a short video of Bhatt discussing why he finds is so significant.
When asked what study stood out most from #ACC22, in terms of immediate clinical applicability, @DLBHATTMD chose the COMPLETE trial analysis detailing the benefits of using complete revascularization vs CLO for improving angina-related QOL in STEMI.https://t.co/2XsZTjD73G pic.twitter.com/WiWTGLSAWT
— Practical Cardiology (@practicalcardio) April 6, 2022
Here are some of Mehta’s slides during his Featured Clinical Research presentation at ACC, via Twitter:
— PHRI | Population Health Research Institute 🇨🇦 (@PHRIresearch) April 2, 2022